The latest from NuvOx

Welcoming the New Kid on the Block; A Phase IIb Study of DDFPe in Large Vessel Strokes

The design for an efficient Phase IIb clinical trial in stroke to test DDFPe in patients with Large Vessel Occlusions.

Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Trial

This randomized, placebo-controlled, double-blind, dose-escalation clinical trial in acute ischemic stroke patients was designed to...

NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial

Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...

Dodecafluoropentane Improves Neurological Function Following Anterior Ischemic Stroke

DDFPe reduces infarct volume and neurological function following anterior ischemic stroke.

DDFPe Extends Window for tPA Therapy in a Rabbit Stroke Model

DDFPe significantly extends the time window for tPA therapy.

DDFPe delays and reduces MRI markers of infarction in a rat stroke model

DDFPe delays and reduces MRI markers of stroke in the early hours following vascular occlusion in a rat stroke model.

Multiple Applications of DDFPe Prevents Death in a Rabbit Stroke Model

Increasing the number of DDFPe applications was significant in reducing the incidence of premature death.

A preliminary PET evaluation of DDFPe effects on rabbit brain hypoxia in stroke

DDFPe alleviates hypoxia in areas of ischemia.

DDFPe Decreases Stroke Size and Improves Neurological Scores in a Rat Stroke Model

DDFPe treatment provides significant neuroprotection when assessed six hours post stroke.

Progress in Dodecafluoropentane Emulsion as a Neuroprotective Agent in a Rabbit Stroke Model

Intravenous DDFPe decreases ischemic stroke infarct volumes. Rapid development is warranted.

Dodecafluoropentane Emulsion Decreases Infarct Volume in a Rabbit Ischemic Stroke Model

Intravenous DDFPe in an animal model decreases infarct volumes and protects brain tissue from ischemia justifying further investigation.